06.30.14 -- Stanford Scientists Find Way To Quicken Drug Discovery; FDA Approval Pushes Novartis Into 21st Century Vaccine Development
FDA Approval Pushes Novartis Into 21st Century Vaccine Development By Trisha Gladd, editor, Pharmaceutical Online and Bioresearch Online
In 2009, the world experienced a global threat in the form of H1N1. Despite a prompt response to the need for a vaccine in the United States, it was still not available until six months later and not enough doses were even produced to cover all Americans. During the year-long battle with the deadly virus, the CDC estimates between 8,870 and 18,300 people died due to H1N1-related complications. In the world of influenza vaccine production using chicken eggs, the response experienced during the H1N1 outbreak is not uncommon. Is this the best our industry can do? Novartis says NO.
November 10 and 11, 2014 | Hyatt Regency, San Francisco, CA
• Who should attend? Pharma and biopharm executives who form and manage outsourcing partnerships.
• What's on the agenda? Educational sessions focused on best practices and industry leaders’ experiences and lessons learned to help you avoid costly mistakes.
Register today! Space is limited. Brought to you by Life Science Leader magazine, BayBio, and Outsourced Pharma.
Sensors designed for incorporation into disposable purification platforms, i.e. single-use tangential flow filtration (TFF), single-use normal flow filtration (NFF) or disposable chromatography must meet a number of challenging requirements.&
This new webinar on improving process development timelines with mini bioreactors details fermentation and bioprocessing data generated by ambr250, a high-throughput, fully automated bioreactor system.